Silence Therapeutics (SLN)

Silence Therapeutics (SLN) Stock Price & Analysis


SLN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.55 - $17.69
Previous Close$14.58
Average Volume (3M)37.59K
Market Cap
Enterprise Value$423.80M
Total Cash (Recent Filing)£71.14M
Total Debt (Recent Filing)£446.00K
Price to Earnings (P/E)-10.2
Mar 13, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding35,893,337
10 Day Avg. Volume56,081
30 Day Avg. Volume37,590
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)25.55
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside166.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Ownership Overview

0.05% Mutual Funds
52.84% Other Institutional Investors
47.12% Public Companies and
Individual Investors


What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.54 and its highest was $17.69 in the past 12 months.
    What is Silence Therapeutics’s market cap?
    Currently, no data Available
    When is Silence Therapeutics’s upcoming earnings report date?
    Silence Therapeutics’s upcoming earnings report date is Mar 13, 2024 which is in 95 days.
      How were Silence Therapeutics’s earnings last quarter?
      Silence Therapeutics released its earnings results on Nov 14, 2023. The company reported -$0.092 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.08.
        Is Silence Therapeutics overvalued?
        According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Silence Therapeutics pay dividends?
          Silence Therapeutics does not currently pay dividends.
          What is Silence Therapeutics’s EPS estimate?
          Silence Therapeutics’s EPS estimate is -$0.08.
            How many shares outstanding does Silence Therapeutics have?
            Silence Therapeutics has 35,936,157 shares outstanding.
              What happened to Silence Therapeutics’s price movement after its last earnings report?
              Silence Therapeutics reported an EPS of -$0.092 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 2.331%.
                Which hedge fund is a major shareholder of Silence Therapeutics?
                Among the largest hedge funds holding Silence Therapeutics’s share is Woodline Partners LP. It holds Silence Therapeutics’s shares valued at 2M.


                  Company Description

                  Silence Therapeutics

                  Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.


                  Top 5 ETFs holding SLN

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold SLN. The ETFs are listed according to market value of SLN within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Arrowhead Pharmaceuticals
                  Alnylam Pharma
                  Crispr Therapeutics AG

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis